IDEXX Laboratories Inc. (IDXX) exhibits 61.8% gross margins and 29.6% return on invested capital within Health Care (Biotechnology: In Vitro & In Vivo Diagnostic Substances), balanced against a 31.1x enterprise multiple and 6.5% implied options volatility.
Sustained 61.8% gross profitability converts into 31.6% operating margin and 29.6% ROIC, outpacing sector cost of capital.
ROIC: 29.6% // GM: 61.8%YoY revenue trajectory of +10.4% paired with 2.33% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +10.4% // FCF YLD: 2.33%Altman Z-Score of 20.99 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.
ALTMAN Z: 20.99 // F-SCORE: 9/9Trading at 42.8x trailing P/E (39.8x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 42.8x // EV/EBITDA: 31.1xOptions market prices a ±6.5% implied move with a 0.69 put/call ratio around $564.00 max pain.
IMPL MOVE: ±6.5% // P/C: 0.69Elevated industry capital intensity and customer concentration in Biotechnology: In Vitro & In Vivo Diagnostic Substances require continuous execution to defend 24.6% net margins.
NET MARGIN: 24.6% // D/E: 0.23x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for IDXX & activate live FRED threshold breach alerts.